Welcome to our dedicated page for HEARTCORE ENTERPRISES SEC filings (Ticker: HTCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartCore Enterprises, Inc. files regulatory reports that document material events for its IPO consulting business, capital structure, governance and Nasdaq listing status. Recent Form 8-K disclosures include operating-results releases, the treatment of HeartCore Co., Ltd. as discontinued operations following its divestiture, and information about the company’s transition toward financial services and capital markets-related activities.
The filings also record amendments to the company’s certificate of incorporation and bylaws, the completed reverse stock split, share-repurchase authorization, Regulation FD exhibits, and notices related to Nasdaq minimum bid price compliance for HTCR common stock.
HeartCore Enterprises (HTCR) reported a small Q3 2025 profit but weaker year-to-date results as it prepares for a major business shift. For the quarter ended September 30, 2025, total revenue from continuing operations was $2,990,329, compared with $16,240,865 a year earlier, reflecting much lower consulting revenue. Gross profit was $1,468,409 and income from continuing operations was a modest loss of $137,122, while discontinued operations contributed income of $488,297, leading to net income of $351,175 and $377,850 attributable to common shareholders.
For the nine months ended September 30, 2025, revenue from continuing operations was $7,052,799 versus $21,270,891 in the prior-year period, and the company posted a net loss of $1,724,700 compared with net income of $7,127,810. Cash and cash equivalents were $1,451,019 and total assets $13,337,171, with shareholders’ equity of $3,824,618. During 2025, HeartCore issued 2,000 Series A convertible preferred shares with an aggregate liquidation preference of $2,256,833 and recorded a $245,820 derivative liability.
A key strategic change is the sale of HeartCore Japan. The board approved a plan on July 24, 2025 to sell 100% of HeartCore Japan, which was treated as a discontinued operation, and the transaction closed on October 31, 2025. This divestiture removes a major historical contributor from future results and leaves the company focused on software development and public-listing consulting through its remaining subsidiaries.
HeartCore Enterprises, Inc. (HTCR) filed a current report to announce that it released financial results for the three and nine months ended September 30, 2025. On November 18, 2025, the company issued a press release describing these results, which is attached as Exhibit 99.1 and incorporated by reference. The company clarifies that the press release and the information in Item 2.02 are being furnished, not filed, which limits their treatment under certain liability provisions of the securities laws.
HeartCore Enterprises (HTCR) reported it received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement under Rule 5550(a)(2). The new deadline is May 1, 2026. If the closing bid price is at least $1.00 for a minimum of 10 consecutive business days during this period, the matter will be closed.
If compliance is not demonstrated, Nasdaq may initiate delisting, which the company could appeal to a Hearings Panel. HeartCore is evaluating potential actions, including a reverse stock split, but has made no decisions.
HeartCore Enterprises (HTCR) amended its 8-K to clarify stockholders’ equity following a completed divestiture. The company sold all equity interests of its Japan subsidiary, HeartCore Inc., to Smith Japan Holdings KK for ¥1,800,418,650, equivalent to approximately $12 million based on a ¥152.82/USD $1 rate, and the sale closed on October 31, 2025.
The purchase price includes staged components: a Closing Payment net of estimated debt; a ¥126,133,200 holdback payable on the later of 180 days after closing or the final net tangible assets determination; a ¥273,866,800 long-term holdback tied to multi-year licensing agreements; and ¥387,078,650 deferred consideration (including ¥322,700,000 principal at 6.65% per annum) due on October 31, 2028. A debt true-up may adjust proceeds based on final debt. Both parties agreed to transition services for six months.
Strategic shift: the company plans to concentrate on its Go IPO consulting business and is assessing alternatives to divest its 51% interest in Sigmaways, Inc. It states stockholders’ equity is in excess of $5,000,000 as of November 4, 2025.
HeartCore Enterprises (HTCR) sold its Japan software subsidiary, HeartCore Japan, to Smith Japan Holdings KK for ¥1,800,418,650 (approximately $12 million), subject to adjustment. The deal closed on October 31, 2025. Payment terms include a Closing Payment of ¥1,013,340,000 less estimated debt, a ¥126,133,200 holdback released after six months or upon final NTA determination, a ¥273,866,800 long‑term holdback tied to multi‑year licensing agreements, and ¥387,078,650 in deferred consideration (¥322,700,000 principal at 6.65% per annum) due October 31, 2028. A debt true‑up may be owed depending on final debt.
The parties agreed to mutual transition services for six months post‑close (accounting/reporting by HeartCore; HR by Purchaser). HeartCore stated it will concentrate on its Go IPO consulting business and is assessing strategic alternatives to divest its 51% interest in Sigmaways, Inc.
HeartCore Enterprises (HTCR) announced a one-time cash distribution of $0.13 per share to common stockholders. The company clarified that a prior press release mistakenly described the payment as a dividend; for U.S. federal tax purposes, it will be treated as a distribution.
Key dates: the record date is November 10, 2025, and the payment date is expected to be November 17, 2025. This update does not change the amount, only the classification and related tax treatment language communicated to investors.
HeartCore Enterprises (HTCR) declared a one-time dividend of $0.13 per share on its common stock. Stockholders of record as of November 10, 2025 will receive the dividend, which is expected to be paid on November 17, 2025. The company also furnished a related press release.
HeartCore Enterprises, Inc. reported the results of its 2025 virtual annual meeting of stockholders held on September 26, 2025. Stockholders elected five directors — Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Yoonji Lee, and Koji Sato — each to serve a one-year term until the next annual meeting and until their successors are elected and qualified. Each nominee received approximately 15.7 million votes in favor, with minimal abstentions and broker non-votes reported.
Stockholders also ratified the appointment of MaloneBailey, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with 17,471,545 votes for, 55,422 against, and 877 abstentions. These results confirm continuity in both board leadership and the company’s external auditor.
HeartCore Enterprises amended its S-1 to disclose an Equity Purchase Agreement with Crom Structured Opportunities Fund I, LP that gives the company the right to direct the accredited selling stockholder to sell up to $25,000,000 of newly issued common stock during a Commitment Period running from June 30, 2025 to June 30, 2027 (subject to termination conditions). The filing shows 23,310,770 shares outstanding as of August 28, 2025 and models issuance of 20,833,333 shares under the agreement (at an assumed $1.20/share) plus conversion of Series A preferred into 1,955,555 common shares (assumed $1.125/share), illustrating material potential dilution. The document also lists transaction fees and references incorporated financial statements and exhibits.
HeartCore Enterprises amended its S-1 to disclose an Equity Purchase Agreement with Crom Structured Opportunities Fund I, LP that gives the company the right to direct the accredited selling stockholder to sell up to $25,000,000 of newly issued common stock during a Commitment Period running from June 30, 2025 to June 30, 2027 (subject to termination conditions). The filing shows 23,310,770 shares outstanding as of August 28, 2025 and models issuance of 20,833,333 shares under the agreement (at an assumed $1.20/share) plus conversion of Series A preferred into 1,955,555 common shares (assumed $1.125/share), illustrating material potential dilution. The document also lists transaction fees and references incorporated financial statements and exhibits.
HeartCore Enterprises, Inc. reports that Nasdaq has confirmed the company is back in compliance with the exchange’s minimum stockholders’ equity requirement. The company previously received a notice on May 24, 2025 stating it did not meet the $2,500,000 stockholders’ equity threshold and did not qualify under alternative market value or net income standards, although trading of its common stock on the Nasdaq Capital Market under the symbol HTCR was not immediately affected.
On August 19, 2025, Nasdaq reviewed HeartCore’s Form 10-Q for the period ended June 30, 2025, which showed stockholders’ equity of $3,559,017, and determined that the company now satisfies the equity listing rule and that the matter is closed. HeartCore also furnished a press release as an exhibit, providing additional communication about these developments.